Table 2.

Common and serious adverse events by treatment assignment

	IGF-1	Placebo	Significance (p)
Common adverse events
Site reactions	88	92	0.509
Headache	22	22	1.000
Hepatotoxicity	14	18	0.460
Change in visual acuity	23	20	0.745
Other abnormal blood chemistries	10	13	0.522
Deep venous thromboses	9	6	0.599
Hypoglycemia	21	9	0.034*
Depression	103	92	0.371
Respiratory failure	55	50	0.723
Serious adverse events
Serious thrombotic events	18	12	0.180
Nonserious thrombotic events	3	1
Any thrombotic event	21	13	0.087
Deep venous thrombosis or pulmonary embolism	11	9	0.412
Cardiac ischemia	6	3	0.254
Cerebral infarction	1	0	0.500
Retinal artery occlusion	3	1	0.313

Only hypoglycemic events reached a significant difference between the two groups.

^*Significant.